CXCL10 and inflammatory bowel disease: The shared IFN-γ response signature between EGCs from patients with UC and helminth-infected mouse EGCs, coupled with associations between elevated Cxcl10 (C-X-C Motif Chemokine Ligand 10) levels and increased IBD risk, underscores the potential therapeutic significance of targeting enteric glia in the management of IBD [83].